The latest proposed hike in rebates due from companies under the UK’s statutory scheme to control the costs of branded medicines is predicted to add further pressure on medicine supply and could even delay or even stop some product launches in the UK, industry sources have warned.
The increase in the rebate under the statutory scheme is driven by a need to align with the higher rebate...